Baxter(US:BAX) Globenewswire·2025-12-15 17:09Core Viewpoint - A class action lawsuit has been filed against Baxter International, Inc. for allegedly misleading investors regarding the safety and efficacy of its Novum LVP devices, which reportedly suffered systemic defects leading to serious patient risks [3][7]. Allegation Details - The lawsuit claims that Baxter failed to disclose systemic defects in the Novum LVP, which caused malfunctions such as underinfusion, overinfusion, and non-delivery of fluids, posing risks of serious injury or death to patients [3]. - Baxter was allegedly aware of multiple device malfunctions, injuries, and deaths related to these defects but did not take adequate remedial measures [3]. - The company’s statements regarding the safety, efficacy, product rollout, customer feedback, and sales prospects of the Novum LVPs are claimed to be materially false and misleading [3]. Next Steps - Investors who purchased Baxter shares during the class period (February 23, 2022, to October 29, 2025) and suffered losses are encouraged to contact the law firm for more information and to discuss their legal rights [4][7]. - There is a deadline of December 15, 2025, for investors to apply to be appointed as lead plaintiff in the lawsuit [7]. About the Law Firm - Bragar Eagel & Squire, P.C. is a nationally recognized law firm that represents individual and institutional investors in complex litigation across the United States [5].